A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

Pfizer

Status and phase: Completed; Phase 2

Conditions: Non-Small-Cell Lung Carcinoma; Adenocarcinoma

Treatments: Drug: Paclitaxel; Drug: Carboplatin; Drug: AG-013736 (axitinib); Drug: Bevacizumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT00600821

A4061030

Details and patient eligibility

About

To determine if the addition of AG-013736 to chemotherapy is beneficial in patients with advanced lung cancer who have not been previously treated.

Enrollment: 118 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced non squamous cell, lung cancer
• No prior treatment for lung cancer except prior adjuvant therapy if last dose was >12 months prior to enrollment

Exclusion criteria

• Prior therapy for advanced lung cancer
• The need for blood-thinners
• Coughing up blood

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

118 participants in 2 patient groups

B

Active Comparator group

Description:

Bevacizumab will be administered in combination with carboplatin and paclitaxel.

Treatment:

Drug: Carboplatin

Drug: Carboplatin

Drug: Bevacizumab

Drug: Paclitaxel

Drug: Paclitaxel

A

Experimental group

Description:

AG-013736 will be administered in combination with carboplatin and paclitaxel.

Treatment:

Drug: Carboplatin

Drug: Carboplatin

Drug: Paclitaxel

Drug: AG-013736 (axitinib)

Drug: Paclitaxel